

Encorium Group Signs Additional New Contracts Valued at \$5.0 Million

Approximately \$10 Million of New Business Contracts Announced During the Past Week

WAYNE, Pa.--([BUSINESS WIRE](#))-- **Encorium Group, Inc.** (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical and biotechnology companies, today announced \$5.0 million of new business contracts with several multinational as well as smaller biopharmaceutical companies. The therapeutic areas included in these awards are cardiovascular diseases, oncology, diabetes, and infectious diseases. Services, which will be provided in both North America and Europe, include medical/scientific consulting, data management, regulatory affairs, project management, field monitoring, and medical monitoring/writing. Revenue recognition for many of these contracts will begin in the current third quarter of 2008 with the remainder expected to occur on a proportional performance basis as services are performed on each project.

Kenneth M. Borow, M.D., Encorium Group's President and Chief Medical and Strategic Development Officer, stated, "Encorium has announced approximately \$10 million of new business contracts during the past week which has resulted in an increase in our current backlog of signed contracts to approximately \$43 million. We are very encouraged by these recent developments and remain confident in our ability to continue to win new business across a wide array of therapeutic areas and geographies."

Kai Lindevall, M.D., Ph.D., Encorium's Chief Executive Officer, commented, "We feel that the successful signing of new business and receipt of new requests for proposals are a clear justification of our recently announced expansion plans. Pharmaceutical and biotechnology companies are recognizing the value of our potential therapeutic and geographic capabilities. That is why I am delighted that we are proceeding with our plans to acquire the oncology-focused CRO Prologue and merge with Linkcon. We feel that with the addition of Prologue's therapeutic expertise and Linkcon's expanding group of CROs in India, Latin America and China/Asia, Encorium will be well positioned to win large multinational CRO contracts that have previously been difficult to attain."

About Encorium Group, Inc.

Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics.

On June 6, 2008, the Company entered into a non-binding letter of intent to acquire Prologue Research International, Inc., a CRO that specializes in a full range of clinical research services for Phase I through Phase IV clinical trials in oncology and oncology-related studies (“Prologue”). This acquisition will broaden Encorium’s therapeutic area expertise in this very important and high-growth area of drug/biologics development.

In addition, on June 11, 2008, the Company entered into a non-binding letter of intent to combine with Fine Success Investments, Ltd., a British Virgin Islands company doing business as Linkcon (“Linkcon”). Linkcon has acquired or will acquire either prior to or simultaneously with the proposed business combination with Encorium (i) a CRO based in India with over 10 years of clinical trial experience; (ii) a CRO operating throughout Latin America, also with over 10 years of clinical trial experience; (iii) a Chinese CRO that holds licenses to conduct clinical trials in the People’s Republic of China and Hong Kong; and (iv) a controlling interest in the Chinese company that holds the license for JK1, a healthcare portal for medical professionals and consumers promoting the exchange of medical information between China and the Western world. This business combination is expected to enhance Encorium’s global profile as a CRO by broadening the Company’s operational services and therapeutic area offerings into established and emerging biopharmaceutical markets across multiple continents.

This press release contains forward-looking statements identified by words such as “estimate,” “project,” “expect,” “intend,” “believe,” “anticipate” and similar expressions. Actual results might differ materially from those projected in, expressed in or implied by the forward-looking statements. Potential risks and uncertainties that could affect the Company’s future operating results and financial condition generally include, without limitation: (i) our success in attracting new business and retaining existing clients and projects; (ii) the size, duration, and timing of clinical trials we are currently managing may change unexpectedly; (iii) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (iv) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (v) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vi) the ability to maintain profit margins in a competitive marketplace; (vii) our ability to attract and retain qualified personnel; (viii) the sensitivity of our business to general economic conditions; (ix) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (x) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; and (xi) our backlog may not be indicative of future revenues and may not generate the revenues expected. You should not place any undue reliance on these forward looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2007 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group’s investor relations department or The Equity Group, Inc.

In addition, this press release contains forward-looking statements regarding the potential acquisition of Prologue and the combination with Linkcon. Those statements involve risks and uncertainties and the actual effects of the transactions could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the timing of the closing, if any, of the acquisition of Prologue and the combination with Linkcon; (ii) the completion to our satisfaction of due diligence regarding both Prologue

and Linkcon; (iii) the acquisition by us of a fairness opinion relating to the purchase price for Linkcon; (iv) our ability to negotiate definitive agreements with Prologue and Linkcon; (v) Linkcon's ability to enter into definitive agreements with the CRO entities to be acquired by Linkcon and Linkcon's ability to complete those transactions pursuant to the existing non-binding term sheets; (vi) Chardan's ability to raise \$25 million for investment in the combined entity; (vii) our ability to obtain the required corporate, stockholder and, if applicable, third-party and governmental approvals; (viii) the possibility that the transaction may not close; (ix) our ability to negotiate mutually acceptable employment arrangements with key employees of Prologue and Linkcon; (x) our ability to successfully integrate the businesses of Prologue and Linkcon; and (xi) the performance of the combined business to operate successfully and generate growth.